DSIJ Mindshare

First patient free of cancer: This stock to benefit from big breakthrough in cancer treatment - Indigenous CAR-T cell therapy!

India's entry into the CAR T-cell therapy arena marks a pivotal moment in the global fight against cancer.

Karan Dsij 0 1794 Article rating: 3.9

In this landscape of innovation, companies like Laurus Lab Ltd stand out as key players driving progress in the transformative cell and gene therapy space. Their strategic collaborations and advancements in product development hold promise for improving treatment outcomes and enhancing accessibility for patients

High ROE and high ROCE penny stock below Rs 80: This consumer foods manufacturing company reports stellar Q3FY24 & 9MFY24 results; PAT zooms over 700 per cent

The stock is down by 10 per cent from its 52-week high of Rs 84 while the stock is up by 33.71 per cent from its 52-week low of Rs 56.84.

Kiran Shroff 0 28622 Article rating: 3.7

The stock is down by 10 per cent from its 52-week high of Rs 84 while the stock is up by 33.71 per cent from its 52-week low of Rs 56.84.

Highest-ever dividend: Multibagger micro-cap stock with low PE and high dividend yield - A must-watch!

The company declared an interim dividend of Rs 15 per share, marking the highest dividend announcement in its history.

Karan Dsij 0 2021 Article rating: 5.0

Stock has demonstrated stellar returns, delivering multibagger gains of 143.09 per cent over the past year and an impressive surge of 224.35 per cent over the last three years. This performance underscores the company's strong growth trajectory and investor confidence in its prospects

RSS
First641642643644646648649650Last
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR